The wedelolactone derivative inhibits estrogen receptor-mediated breast, endometrial, and ovarian cancer cells growth

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Xu, Defeng ^a,b   Lin, Tzu Hua ^b   Yeh, Chiuan Ren ^b   Cheng, Max A ^b   Chen, Lu Min ^c   Chang, Chawnshang ^b,c   Yeh, Shuyuan ^b  

^a CHANGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 BUTOXY 1,8,9 TRIHYDROXY 6H BENZOFURO[3,2 C]BENZOPYRAN 6 ONE; CELL NUCLEUS RECEPTOR; CYCLIN D1; ESTRADIOL; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; PROGESTERONE RECEPTOR; TERT BUTOXYCARBONYLPHENYLALANYLHISTIDINE N [1 (CYCLOHEXYLMETHYL) 2 HYDROXY 2 (1H IMIDAZOL 2 YL)ETHYL]AMIDE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; WEDELOLACTONE; COUMARIN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; ENDOMETRIAL CANCER CELL LINE; FEMALE; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSACTIVATION; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY;

BREAST NEOPLASMS; CELL PROLIFERATION; COUMARINS; CYCLIN D1; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84907384359     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/713263     Document Type: Article

References (45)

1. L. W. Rice, "Hormone prevention strategies for breast, endometrial and ovarian cancers," Gynecologic Oncology, vol. 118, no. 2, pp. 202-207, 2010.
2. Y. M. Shah and B. G. Rowan, "The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor α promoter interaction and elevated steroid receptor coactivator 1 activity," Molecular Endocrinology, vol. 19, no. 3, pp. 732-748, 2005.
3. C. K. Osborne, H. Zhao, and S. A. W. Fuqua, "Selective estrogen receptor modulators: structure, function, and clinical use," Journal of Clinical Oncology, vol. 18, no. 17, pp. 3172-3186, 2000.
4. G. Freiss, C. Puech, and F. Vignon, "Extinction of insulin-like growth factor-i mitogenic signaling by antiestrogen-stimulated fas-associated protein tyrosine phosphatase-1 in human breast cancer cells," Molecular Endocrinology, vol. 12, no. 4, pp. 568-579, 1998.
5. M. A. H. Mollik, M. S. H. Hossan, A. K. Paul, M. Taufiq-Ur-Rahman, R. Jahan, and M. Rahmatullah, "A comparative analysis of medicinal plants used by folk medicinal healers in three districts of Bangladesh and inquiry as to mode of selection of medicinal plants," Ethnobotany Research and Applications, vol. 8, pp. 195-218, 2010.
6. A. M. S. Pereira, B. W. Bertoni, A. Menezes Jr., P. S. Pereira, and S. C. Franca, "Soil pH and production of biomass and wedelolactone in field grown Eclipta alba," Journal of Herbs, Spices and Medicinal Plants, vol. 6, no. 1, pp. 43-48, 1998.
7. M. Kobori, Z. Yang, D. Gong et al., "Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex," Cell Death and Differentiation, vol. 11, no. 1, pp. 123-130, 2004.
8. A. K. Saxena, B. Singh, and K. K. Anand, "Hepatoprotective effects of Eclipta alba on subcellular levels in rats," Journal of Ethnopharmacology, vol. 40, no. 3, pp. 155-161, 1993.
9. A. M. Soares, F. K. Ticli, S. Marcussi et al., "Medicinal plants with inhibitory properties against snake venoms," Current Medicinal Chemistry, vol. 12, no. 22, pp. 2625-2641, 2005.
10. H. Wagner, B. Geyer, and Y. Kiso, "Coumestans as the main active principles of the liver drugs Eclipta alba and Wedelia calendulacea," Planta Medica, vol. 5, pp. 370-374, 1986.
11. L. C. Diogo, R. S. Fernandes, S. Marcussi et al., "Inhibition of snake venoms and phospholipases A2 by Extracts from native and genetically modified Eclipta alba: isolation of active coumestans," Basic and Clinical Pharmacology and Toxicology, vol. 104, no. 4, pp. 293-299, 2009.
12. N. Uddin, A. Rahman, N. U. Ahmed et al., "Antioxidant, cytotoxic and antimicrobial properties of Eclipta albaethanol extract," International Journal of Biological and Medical Research, vol. 1, no. 4, pp. 341-334, 2010.
13. F. M. Lin, L. R. Chen, E. H. Lin et al., "Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells," Carcinogenesis, vol. 28, no. 12, pp. 2521-2529, 2007.
14. C. H. Tsai, F. M. Lin, Y. C. Yang et al., "Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice," Clinical Cancer Research, vol. 15, no. 17, pp. 5435-5444, 2009.
15. J. R. Vender, M. D. Laird, and K. M. Dhandapani, "Inhibition of nfκb reduces cellular viability in gh3 pituitary adenoma cells," Neurosurgery, vol. 62, no. 5, pp. 1122-1128, 2008.
16. M. Chen, J. Ni, H. Chang, C. Lin, M. Muyan, and S. Yeh, "CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells," Carcinogenesis, vol. 30, no. 5, pp. 841-850, 2009.
17. M. Chen, J. Ni, Y. Zhang, M. Muyan, and S. Yeh, "ERAP75 functions as a coactivator to enhance estrogen receptor α transactivation in prostate stromal cells," Prostate, vol. 68, no. 12, pp. 1273-1282, 2008.
18. D. Xu, T. Lin, S. Li et al., "Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells," Cancer Letters, vol. 316, no. 1, pp. 11-22, 2012.
19. D. Xu, T. Lin, C. Zhang et al., "The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells," Prostate, vol. 72, no. 7, pp. 803-816, 2012.
20. S. Yeh, Y. Hu, M. Rahman et al., "Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 21, pp. 11256-11261, 2000.
21. S. Yeh, H. K. Lin, H. Y. Kang, T. H. Thin, M. Lin, and C. Chang, "From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 10, pp. 5458-5463, 1999.
22. J. Ni, S. Pang, and S. Yeh, "Differential retention of α-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells," Prostate, vol. 67, no. 5, pp. 463-471, 2007.
23. S. Tenbaum and A. Baniahmad, "Nuclear receptors: structure, function and involvement in disease," International Journal of Biochemistry and Cell Biology, vol. 29, no. 12, pp. 1325-1341, 1997.
24. N. Harada, K. Inoue, R. Yamaji, Y. Nakano, and H. Inui, "Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells," Cancer Science, vol. 103, no. 6, pp. 1022-1027, 2012.
25. J. H. Choi, K. T. Lee, and P. C. K. Leung, "Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth," Carcinogenesis, vol. 32, no. 4, pp. 589-596, 2011.
26. Y. Miyoshi, K. Murase, M. Saito, M. Imamura, and K. Oh, "Mechanisms of estrogen receptor-α upregulation in breast cancers," Medical Molecular Morphology, vol. 43, no. 4, pp. 193-196, 2010.
27. J. S. Tong, Q. H. Zhang, Z. B. Wang et al., "ER-α36, a novel variant of ER-α, mediates estrogen stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway," PLoS ONE, vol. 5, no. 11, Article ID e15408, 2010.
28. M. C. Louie, A. McClellan, C. Siewit, and L. Kawabata, "Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance," Molecular Cancer Research, vol. 8, no. 3, pp. 343-352, 2010.
29. S. Misiti, S. Nanni, G. Fontemaggi et al., "Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells," Molecular and Cellular Biology, vol. 20, no. 11, pp. 3764-3771, 2000.
30. C. Yang, L. Chen, C. Li, M. C. Lynch, C. Brisken, and E. V. Schmidt, "Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression," Molecular and Cellular Biology, vol. 30, no. 12, pp. 3111-3125, 2010.
31. N. A. Binai, A. Damert, G. Carra et al., "Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells," International Journal of Cancer, vol. 127, no. 1, pp. 55-66, 2010.
32. S. Bose, S. Chandran, J. M. Mirocha, and N. Bose, "The Akt pathway in human breast cancer: a tissue-array-based analysis," Modern Pathology, vol. 19, no. 2, pp. 238-245, 2006.
33. S. Haftchenary, M. Avadisian, and P. T. Gunning, "Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report," Anti-Cancer Drugs, vol. 22, no. 2, pp. 115-127, 2011.
34. D. Lane, N. Goncharenko-Khaider, C. Rancourt, and A. Piché, "Ovarian cancer ascites protects from TRAIL-induced cell death through αvB5 integrin-mediated focal adhesion kinase and Akt activation," Oncogene, vol. 29, no. 24, pp. 3519-3531, 2010.
35. K. Stemke-Hale, A. M. Gonzalez-Angulo, A. Lluch et al., "An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer," Cancer Research, vol. 68, no. 15, pp. 6084-6091, 2008.
36. J. Z. Tang, X. J. Kong, A. Banerjee et al., "STAT3α is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone," Endocrinology, vol. 151, no. 9, pp. 4133-4145, 2010.
37. J. J. Wallin, J. Guan, W. W. Prior et al., "Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer," Science Translational Medicine, vol. 2, no. 48, Article ID 48ra66, 2010.
38. S. H. Park, L. W. Cheung, A. S. Wong, and P. C. Leung, "Estrogen regulates snail and slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor α,"Molecular Endocrinology, vol. 22, no. 9, pp. 2085-2098, 2008.
39. E. Weiderpass, I. Persson, H. Melhus, S. Wedrén, A. Kindmark, and J. A. Baron, "Estrogen receptor α gene polymorphisms and endometrial cancer risk," Carcinogenesis, vol. 21, no. 4, pp. 623-627, 2000.
40. L. Tian, Z. Wu, Y. Zhao et al., "Differential induction of LRP16 by liganded and unliganded estrogen receptor α in SKOV3 ovarian carcinoma cells," Journal of Endocrinology, vol. 202, no. 1, pp. 167-177, 2009.
41. C. Giacinti and A. Giordano, "RB and cell cycle progression," Oncogene, vol. 25, no. 38, pp. 5220-5227, 2006.
42. Z. Wang, S. Kyo, Y. Maida et al., "Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells," Oncogene, vol. 21, no. 22, pp. 3517-3524, 2002.
43. M. Vita and M. Henriksson, "The Myc oncoprotein as a therapeutic target for human cancer," Seminars in Cancer Biology, vol. 16, no. 4, pp. 318-330, 2006.
44. S. Bircan, A. Ensari, S. Ozturk, N. Erdogan, I. Dundar, and F. Ortac, "Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium," Pathology and Oncology Research, vol. 11, no. 1, pp. 32-39, 2005.
45. C. H. Chien, F. F. Wang, and T. C. Hamilton, "Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells,"Molecular and Cellular Endocrinology, vol. 99, no. 1, pp. 11-19, 1994.